Supplementary Table 1.
Clinical Characteristics of the FFPE Cohort
| Patient ID | Age | Gender | CD/UC | Disease extent/Montreal | CRP | Endoscopic evidence active disease | Medications |
|---|---|---|---|---|---|---|---|
| 1 | 26 | F | CD | A2L3B2p | <5 | Yes | Steroids |
| 2 | 37 | F | CD | A?L3B3p | 9 | Yes | None |
| 3 | 26 | F | CD | A1L1B3 | 52 | Yes | Thiopurine |
| 4 | 38 | F | CD | A?L3B3p | 25 | Yes | Adalimumab and thiopurine |
| 5 | 19 | M | CD | A1L1B2 | 7 | Yes | Adalimumab |
| 9 | 18 | F | CD | A1L3B3 | <5 | Yes | Steroids |
| 10 | 23 | M | CD | A2L3B2p | 35 | Yes | Adalimumab and thiopurine |
| 11 | 36 | M | CD | A1L3B2p | Yes | Adalimumab and thiopurine | |
| 12 | 64 | F | CD | A3L3B3 | 53 | Yes | Adalimumab and steroids |
| 6 | 35 | F | UC | E3 | Yes | None | |
| 7 | 50 | F | UC | E3 | 37 | Yes | None |
| 8 | 34 | M | UC | E3 | <5 | Yes | Infliximab |
| 13 | 47 | M | UC | E1 | 34 | Yes | None |
| 14 | 14 | F | UC | E3 | 31 | Yes | Steroids |
| 15 | 28 | M | UC | E3 | 9 | Yes | Biologics and steroids |
| 16 | 16 | M | UC | E3 | 10 | Yes | Immunomodulator and steroids |
| 17 | 28 | F | UC | E3 | 32 | Yes | Tacrolimus |
CD, Crohn’s disease; CRP, C-reactive protein; FFPE, formalin fixed and paraffin embedded; UC, ulcerative colitis.